Notable Quotes
| "INO announced a collaboration with Roche to evaluate their DNA-based immunotherapies in advanced bladder cancer." | ❭ |
| "We view RVX's shares as undervalued, and in a position to provide long-term upside potential." | ❭ |
| "Early completion of enrollment for PERSIST, at 12% higher enrollment than targeted, has positive implications for DRRX's Posimir." | ❭ |
More Experts
| "INO announced the second collaboration study involving the company’s INO-5401 T-cell activating immunotherapy." | ❭ |
